(Q38971612)

8 September 2017

1 reference

title

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. (English)

1 reference

8 September 2017

1 reference

1 reference

Jennifer N Clements

1

1 reference

8 September 2017

Tiffaney Threatt

series ordinal

2

1 reference

8 September 2017

Eileen Ward

series ordinal

3

1 reference

8 September 2017

Kayce M Shealy

series ordinal

4

1 reference

8 September 2017

4 October 2016

1 reference

Clinical Pharmacokinetics

8 September 2017

1 reference

8 September 2017

56

1 reference

8 September 2017

5

1 reference

8 September 2017

449-458

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-016-0464-6

8 September 2017

0 references

cites work

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

AACE/ACE comprehensive diabetes management algorithm 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month e

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Biotransformation of insulin glargine after subcutaneous injection in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Usability of the Gla-300 Injection Device Compared With Three Other Commercialized Disposable Insulin Pens: Results of an Interview-Based Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0464-6

New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27699623

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New long-acting insulin analogs: from clamp studies to clinical practice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27699623

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40262-016-0464-6

1 reference

Dimensions Publication ID

8 September 2017

0 references

1 reference